CL2009002187A1 - Composicion farmaceutica anticonceptiva que comprende 5-metil-(6s)-tetrahidrofolato, estrogenos y/o progestagenos, opcionalmente vitamina b6 y/o vitamina b2 y coadyuvantes/vehiculos; kit; proceso para prepararla; uso para reducir el riesgo de enfermedades y malformaciones congenitas por carencia de folato (div. sol. 1130-06). - Google Patents

Composicion farmaceutica anticonceptiva que comprende 5-metil-(6s)-tetrahidrofolato, estrogenos y/o progestagenos, opcionalmente vitamina b6 y/o vitamina b2 y coadyuvantes/vehiculos; kit; proceso para prepararla; uso para reducir el riesgo de enfermedades y malformaciones congenitas por carencia de folato (div. sol. 1130-06).

Info

Publication number
CL2009002187A1
CL2009002187A1 CL2009002187A CL2009002187A CL2009002187A1 CL 2009002187 A1 CL2009002187 A1 CL 2009002187A1 CL 2009002187 A CL2009002187 A CL 2009002187A CL 2009002187 A CL2009002187 A CL 2009002187A CL 2009002187 A1 CL2009002187 A1 CL 2009002187A1
Authority
CL
Chile
Prior art keywords
vitamin
tetrahydrofolate
estrogens
kit
methyl
Prior art date
Application number
CL2009002187A
Other languages
English (en)
Spanish (es)
Inventor
Muller Kristina
Strothmann Kai
Welch Smith Gavin
Blode Hartmut
Moser Rudolf
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37396913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009002187(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE102005023301A external-priority patent/DE102005023301B4/de
Priority claimed from DE102006016285A external-priority patent/DE102006016285A1/de
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CL2009002187A1 publication Critical patent/CL2009002187A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
CL2009002187A 2005-05-13 2009-12-18 Composicion farmaceutica anticonceptiva que comprende 5-metil-(6s)-tetrahidrofolato, estrogenos y/o progestagenos, opcionalmente vitamina b6 y/o vitamina b2 y coadyuvantes/vehiculos; kit; proceso para prepararla; uso para reducir el riesgo de enfermedades y malformaciones congenitas por carencia de folato (div. sol. 1130-06). CL2009002187A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005023301A DE102005023301B4 (de) 2005-05-13 2005-05-13 Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat
DE102006016285A DE102006016285A1 (de) 2006-04-03 2006-04-03 Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat

Publications (1)

Publication Number Publication Date
CL2009002187A1 true CL2009002187A1 (es) 2010-10-01

Family

ID=37396913

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2009002187A CL2009002187A1 (es) 2005-05-13 2009-12-18 Composicion farmaceutica anticonceptiva que comprende 5-metil-(6s)-tetrahidrofolato, estrogenos y/o progestagenos, opcionalmente vitamina b6 y/o vitamina b2 y coadyuvantes/vehiculos; kit; proceso para prepararla; uso para reducir el riesgo de enfermedades y malformaciones congenitas por carencia de folato (div. sol. 1130-06).
CL2010000989A CL2010000989A1 (es) 2005-05-13 2010-09-21 Uso de 5-metil-(6s)-tetrahidrofolato, drospirenona y etinilestradiol, en ausencia de viatamina b12, para preparar un medicamento util para prolongar la reduccion del riesgo de enfermedades y malformaciones congenitas provocadas por carencias de folato seleccionadas de grupo definido (sol.div. 1130-06).

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2010000989A CL2010000989A1 (es) 2005-05-13 2010-09-21 Uso de 5-metil-(6s)-tetrahidrofolato, drospirenona y etinilestradiol, en ausencia de viatamina b12, para preparar un medicamento util para prolongar la reduccion del riesgo de enfermedades y malformaciones congenitas provocadas por carencias de folato seleccionadas de grupo definido (sol.div. 1130-06).

Country Status (37)

Country Link
US (2) US20080160004A1 (OSRAM)
EP (3) EP2116249B2 (OSRAM)
JP (2) JP2008540482A (OSRAM)
KR (2) KR20080028369A (OSRAM)
CN (2) CN101954083A (OSRAM)
AR (1) AR054123A1 (OSRAM)
AT (2) ATE555791T1 (OSRAM)
AU (1) AU2006245921A1 (OSRAM)
BR (1) BRPI0611443B8 (OSRAM)
CA (1) CA2608639C (OSRAM)
CL (2) CL2009002187A1 (OSRAM)
CR (1) CR9531A (OSRAM)
CY (2) CY1109261T1 (OSRAM)
DE (1) DE502006003617D1 (OSRAM)
DK (2) DK2116249T3 (OSRAM)
DO (1) DOP2006000110A (OSRAM)
EA (2) EA014664B1 (OSRAM)
EC (1) ECSP078001A (OSRAM)
ES (2) ES2325600T3 (OSRAM)
GT (1) GT200600200A (OSRAM)
HR (1) HRP20090418T1 (OSRAM)
IL (1) IL187340A (OSRAM)
MA (1) MA29448B1 (OSRAM)
MY (1) MY147362A (OSRAM)
NO (1) NO345807B1 (OSRAM)
PE (1) PE20061415A1 (OSRAM)
PL (2) PL2116249T3 (OSRAM)
PT (2) PT2116249E (OSRAM)
RS (2) RS50972B (OSRAM)
SG (1) SG169973A1 (OSRAM)
SI (2) SI2116249T1 (OSRAM)
SV (1) SV2008002527A (OSRAM)
TN (1) TNSN07418A1 (OSRAM)
TW (1) TWI380820B (OSRAM)
UY (1) UY29527A1 (OSRAM)
WO (1) WO2006120035A2 (OSRAM)
ZA (2) ZA200710811B (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
CA2665788A1 (en) * 2006-07-06 2008-01-10 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical preparations for contraception and for preventing the risk of congenital malformations
EP1891959A1 (de) * 2006-08-14 2008-02-27 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
MX2009010763A (es) * 2007-04-05 2009-10-28 Bayer Schering Pharma Ag NUEVO REGIMEN DE DROSPIRENONA/17ß-ESTRADIOL, PRODUCTO FARMACEUTICO COMBINADO Y CONJUNTO DE ELEMENTOS (KIT) PARA SU APLICACION.
EA201070715A1 (ru) * 2007-12-20 2011-02-28 Тева Вимен'С Хелс, Инк. Режимы дозирования, фармацевтические композиции и упаковки для экстренной контрацепции
TW200946542A (en) * 2008-03-10 2009-11-16 Vladimir Hanes New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
TW200942242A (en) * 2008-03-10 2009-10-16 Rolf Schurmann New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
MX356702B (es) 2010-04-15 2018-06-11 Bayer Ip Gmbh Formas de dosificación sólidas orales con dosis muy bajas para la hrt.
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
EP2617422A1 (en) * 2012-01-20 2013-07-24 Isofol Medical AB Anti-tumor activity of reduced folates like methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate
EP2781214A1 (en) 2013-03-22 2014-09-24 Chemo Research, S.L. Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca)
CN104490887A (zh) * 2014-09-04 2015-04-08 连云港金康和信药业有限公司 (6s)-5-甲基-四氢叶酸钙盐的稳定药物组合物
MY195019A (en) 2015-06-18 2023-01-03 Estetra Sprl Orodispersible dosage unit containing an estetrol component
JP6866560B2 (ja) 2015-06-18 2021-04-28 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロール成分を含有する口腔内崩壊性投与単位
HUE054589T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Szájban diszpergálódó esztetrol tartalmú tabletta
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
CN106336444A (zh) * 2016-08-23 2017-01-18 国家卫生计生委科学技术研究所 一种新晶型炔雌醇
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK174724B1 (da) * 1986-07-15 2003-10-06 Wyeth Corp Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet
ZA939565B (en) * 1993-12-21 1994-08-11 Applied Analytical Ind Inc Method for preparing low dose pharmaceutical products.
US6083528A (en) * 1995-09-28 2000-07-04 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
AU7522896A (en) * 1995-10-27 1997-05-15 Merck & Co., Inc. Wet granulation formulation of a growth hormone secretagogue
CN1122456C (zh) 1996-01-31 2003-10-01 南亚拉巴马医学科学基金会 含有天然的还原叶酸盐异构体的食品和维生素制品
CH693255A5 (de) * 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
UA68365C2 (en) * 1997-11-06 2004-08-16 Wyeth Corp Peroral contraception by combination of anti-estrogen and progestin
CN1240387C (zh) * 1998-04-17 2006-02-08 奥索一麦克尼尔药品公司 含有叶酸的药用组合物及其用途和给药系统
US7014865B1 (en) 1998-10-19 2006-03-21 Merck Patent Gmbh Natural formulation for the treatment and prevention of depression, containing St. John's Wort and derivatives of dihydro- and tetrahydrofolic acid
CA2348693C (en) * 1998-10-19 2008-07-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung Natural formulation for the treatment and prevention of depression, containing st john's wort and derivatives of dihydro- and tetrahydrofolic acid
CH693905A5 (de) 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
HU225779B1 (en) 1999-07-28 2007-08-28 Chinoin Gyogyszer Es Vegyeszet Pharmaceutical composition containing paracetamol and drotaverine and process for producing it
ES2319750T3 (es) 1999-08-31 2009-05-12 Bayer Schering Pharma Aktiengesellschaft Composicion farmaceutica que comprende etinilestradiol y drospirenona para usar como anticonceptivo.
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US6479545B1 (en) 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
DE10022510A1 (de) 2000-05-10 2001-11-15 Basf Ag Zusammensetzungen enthaltend Folsäure und reduziertes Folat
CA2433949A1 (en) * 2000-12-14 2002-10-24 Tufts University Compositions and methods for treating an arthritic condition
US20030045510A1 (en) * 2000-12-15 2003-03-06 Schloss Caroline Maxine Estrogen-plus
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
US20040220118A1 (en) * 2001-02-02 2004-11-04 Bland Jeffrey S. Medical composition for balancing bodily processes
US20060034954A1 (en) * 2001-02-02 2006-02-16 Bland Jeffrey S Medical composition for balancing bodily processes
CA2476940C (en) * 2002-02-21 2011-11-01 Herman Jan Tijmen Coelingh Bennink Pharmaceutical compositions comprising one or more steroids, one or more tetrahydrofolate components and vitamin b12
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.

Also Published As

Publication number Publication date
GT200600200A (es) 2007-03-23
TWI380820B (zh) 2013-01-01
PE20061415A1 (es) 2007-01-26
MA29448B1 (fr) 2008-05-02
RS50972B (sr) 2010-10-31
ATE555791T1 (de) 2012-05-15
HRP20090418T1 (hr) 2009-09-30
EP2116249B1 (de) 2012-05-02
ZA200908894B (en) 2025-01-29
EA028530B1 (ru) 2017-11-30
CL2010000989A1 (es) 2011-02-18
SV2008002527A (es) 2008-03-27
NO345807B1 (no) 2021-08-16
CY1114403T1 (el) 2016-08-31
PL1888077T3 (pl) 2009-12-31
EP2298307A1 (de) 2011-03-23
KR20080028369A (ko) 2008-03-31
HK1118729A1 (en) 2009-02-20
JP2008540482A (ja) 2008-11-20
JP2013166753A (ja) 2013-08-29
US20080160004A1 (en) 2008-07-03
US10463666B2 (en) 2019-11-05
SI2116249T1 (sl) 2013-02-28
PL2116249T3 (pl) 2013-06-28
SG169973A1 (en) 2011-04-29
RS52651B (sr) 2013-06-28
EA200901393A1 (ru) 2010-02-26
ES2325600T3 (es) 2009-09-09
ZA200710811B (en) 2012-06-27
PT1888077E (pt) 2009-07-20
EP2116249B2 (de) 2023-04-05
CY1109261T1 (el) 2014-07-02
DOP2006000110A (es) 2012-06-15
WO2006120035A2 (de) 2006-11-16
KR101598735B1 (ko) 2016-03-02
WO2006120035A3 (de) 2007-02-15
EA200702349A1 (ru) 2008-04-28
BRPI0611443A2 (pt) 2010-09-08
BRPI0611443B1 (pt) 2020-07-21
CN101198332A (zh) 2008-06-11
CN101954083A (zh) 2011-01-26
EP1888077A2 (de) 2008-02-20
ES2387525T5 (es) 2024-07-05
UY29527A1 (es) 2006-12-29
AU2006245921A1 (en) 2006-11-16
ECSP078001A (es) 2008-01-23
ATE429917T1 (de) 2009-05-15
PT2116249E (pt) 2012-08-07
CR9531A (es) 2008-02-21
EP1888077B1 (de) 2009-04-29
IL187340A0 (en) 2011-08-01
US20160095860A1 (en) 2016-04-07
KR20140069175A (ko) 2014-06-09
TW200711651A (en) 2007-04-01
BRPI0611443B8 (pt) 2021-05-25
AR054123A1 (es) 2007-06-06
ES2387525T3 (es) 2012-09-25
JP5883810B2 (ja) 2016-03-15
MY147362A (en) 2012-11-30
DK1888077T3 (da) 2009-08-17
EP2116249A1 (de) 2009-11-11
DE502006003617D1 (de) 2009-06-10
SI1888077T1 (sl) 2009-10-31
EA014664B1 (ru) 2010-12-30
TNSN07418A1 (en) 2009-03-17
CA2608639C (en) 2013-04-30
DK2116249T3 (da) 2012-08-20
IL187340A (en) 2015-03-31
NO20076408L (no) 2008-02-12
CN101198332B (zh) 2012-07-18
CA2608639A1 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
CL2009002187A1 (es) Composicion farmaceutica anticonceptiva que comprende 5-metil-(6s)-tetrahidrofolato, estrogenos y/o progestagenos, opcionalmente vitamina b6 y/o vitamina b2 y coadyuvantes/vehiculos; kit; proceso para prepararla; uso para reducir el riesgo de enfermedades y malformaciones congenitas por carencia de folato (div. sol. 1130-06).
UY30462A1 (es) Composicion farmacéuticas que contiene un acido tetrahidrofolico.
CL2007001961A1 (es) Composicion farmaceutica que contiene a) 2,0 mg de dienogest y 0,015 mg de etinilestradiol y (6s)-5-metil-tetrahidrofolato y uno o mas excipiente/vehiculos; kit; uso para la anticoncepcion femeneina y reducir el riesgo d malformaciones congenitas debidas a la falta de folato en el embarazo.
ATE543489T1 (de) Orale dosierformen mit progesteron und verwendungs- und herstellungsverfahren dafür
ATE540680T1 (de) Pharmazeutische aripiprazol-zusammensetzungen
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
SK4070U (sk) Farmaceutická kompozícia na riadené uvoľňovanie účinných látok
ATE538797T1 (de) Pharmazeutische zusammensetzungen mit neuroaktivem steroid und verwendungen davon
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
DE602004011398D1 (de) Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779
FR2909284B1 (fr) Nouvelles compositions sous forme d'onguent sans vaseline comprenant un derive de vitamine d et eventuellement un anti-inflammatoire steroidien
PE20070329A1 (es) Composiciones con estrogenos y metodos terapeuticos para su uso
AP2004003046A0 (en) Dosage regimen and pharmaceutical composition for emergency contraception.
BRPI0412458A (pt) composições farmacêuticas oralmente dosadas compreendendo um agente de liberação na forma micronizada
EP1993567A4 (en) PER OS ADMINISTRABLE GALLIUM PREPARATIONS AND METHODS OF USE
ATE378070T1 (de) Zusammensetzung mit fulvestrant
EA200701091A1 (ru) Противозачаточный фармацевтический препарат
DOP2007000117A (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
AR034810A1 (es) Composicion farmaceutica para la administracion por via nasal de estradiol y de noretisterona
ATE429905T1 (de) Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung
JO2561B1 (en) Pharmaceutical composition comprising progestagen and / or estrogen and 5-methyl-6-c-tetrahydrofolate
CR7245A (es) Formulacion de suspension oral estabilizada
HN2002000049A (es) Nuevos compuestos antiinflamatorios de triazolopiridinas